An exploratory analysis suggested that the combination of low tumor cell PD-L1 expression and a low tumor mutation burden predicted an extremely poor immunotherapy response.<h4>Conclusions</h4>Tumor mutation burden and PD-L1 represent potential predictive biomarkers for response to combination CKI therapy, while LDH and BRAF offer limited predictive value. This evidence concerns the gene BRAF and neoplasm.